A phase II study of nivolumab cabiralizumab and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Pancreatic Cancer
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Histologically confirmed locally advanced, unresectable pancreatic cancer 2. Completion of at least 2 months, but no more than 6 months of standard induction chemotherapy for locally advanced pancreatic cancer 3. Patients must agree to pretreatment and on treatment tumor biopsy
You may not be eligible for this study if the following are true:
-
1. Resectable, borderline resectable or metastatic disease 2. Patients with active, known, or suspected autoimmune disease 3. Known human immunodeficiency virus (HIV), known active hepatitis A, or known hepatitis B or C infection
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.